Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma.
Stefano IndraccoloGiuseppe LombardiAngelo Paolo Dei TosLorenza PasqualiniSilvia GiuncoRaffaella MarcatoAlessandra GaspariniCinzia CandiottoSilvia NalioPasquale FiducciaGiuseppe Nicolò FanelliArdi PambukuAlessandro Della PuppaDomenico D'AvellaLaura BonaldiMarina Paola GardimanRoberta BertorelleAnita De RossiVittorina ZagonelPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Multilevel profiling of MMR-deficient rGBM uncovered hypermutated genotype uncoupled from enriched expression of immune-related markers. Assessment of MHC class I expression and TMB should be included in protocols aiming to identify rGBM patients potentially eligible for treatment with drugs targeting immune-checkpoint inhibitors.
Keyphrases
- poor prognosis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- single cell
- acute lymphoblastic leukemia
- gene expression
- acute myeloid leukemia
- dna methylation
- prognostic factors
- peritoneal dialysis
- genome wide
- diffuse large b cell lymphoma
- binding protein
- multiple myeloma
- combination therapy
- patient reported outcomes
- wild type